Induction of nerve growth factor by phorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway

[1]  P. Massion,et al.  Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung , 2009, Molecular Cancer Therapeutics.

[2]  Y. Liu,et al.  Five new phorbol esters with cytotoxic and selective anti-inflammatory activities from Croton tiglium. , 2015, Bioorganic & medicinal chemistry letters.

[3]  Allyson L Dailey,et al.  Bacteria-induced static batch fungal fermentation of the diterpenoid cyathin A3, a small-molecule inducer of nerve growth factor , 2011, Journal of Industrial Microbiology & Biotechnology.

[4]  C. Belka,et al.  Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology , 2002, International journal of radiation biology.

[5]  G. Mills,et al.  Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway , 1999, Oncogene.

[6]  P. Cohen,et al.  BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. , 2007, The Biochemical journal.

[7]  N. Wilson,et al.  Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target , 2012, Fibrogenesis & tissue repair.

[8]  A. Harris,et al.  Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. , 1995, British Journal of Cancer.

[9]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[10]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[11]  P. Cohen,et al.  MSK1 and MSK2 Are Required for the Mitogen- and Stress-Induced Phosphorylation of CREB and ATF1 in Fibroblasts , 2002, Molecular and Cellular Biology.

[12]  F. Gage,et al.  Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain , 1991, Annals of neurology.

[13]  John C Reed,et al.  Heat-shock proteins as regulators of apoptosis , 2003, Oncogene.

[14]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[15]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[16]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[17]  P. Cohen,et al.  BI-D 1870 is a specific inhibitor of the p 90 RSK ( ribosomal S 6 kinase ) isoforms in vitro and in vivo , 2006 .

[18]  Shigeo Ohno,et al.  Protein Kinase C δ Activates the MEK-ERK Pathway in a Manner Independent of Ras and Dependent on Raf* , 1996, The Journal of Biological Chemistry.

[19]  D. Alkon,et al.  Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Andric,et al.  Effect of PMA-induced protein kinase C activation on development and apoptosis in early zebrafish embryos. , 2016, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[21]  H. Ruan,et al.  BAD Ser-155 Phosphorylation Regulates BAD/Bcl-XL Interaction and Cell Survival* , 2000, The Journal of Biological Chemistry.

[22]  Rossen Donev,et al.  Neuronal death in Alzheimer’s disease and therapeutic opportunities , 2009, Journal of cellular and molecular medicine.

[23]  Philip R. Cohen,et al.  Paradoxical activation of Raf by a novel Raf inhibitor. , 1999, Chemistry & biology.

[24]  A. Newton,et al.  Mechanism of Interaction of Protein Kinase C with Phorbol Esters , 1995, The Journal of Biological Chemistry.

[25]  C. Cohen,et al.  Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis , 2003, Modern Pathology.

[26]  A. Balmain,et al.  K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling , 2015, Cell.

[27]  D. Alkon,et al.  A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts , 2009, Neurobiology of Disease.

[28]  C. Yang,et al.  Enhancement of the nonamyloidogenic pathway by exogenous NGF in an Alzheimer transgenic mouse model , 2014, Neuropeptides.

[29]  E. Petricoin,et al.  Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Gottesman,et al.  The tumor promoter phorbol 12-myristate 13-acetate induces a program of altered gene expression similar to that induced by platelet-derived growth factor and transforming oncogenes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Dewson,et al.  Molecular biology of Bax and Bak activation and action. , 2011, Biochimica et biophysica acta.

[32]  T. Kinoshita,et al.  Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. , 2005, Biochemical and biophysical research communications.

[33]  J. Dickenson,et al.  Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth , 2018, European journal of pharmacology.

[34]  T. Golde,et al.  Rational targeting of Notch signaling in cancer , 2008, Oncogene.

[35]  C. M. Davenport,et al.  Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. , 1999, Science.

[36]  J. Kordower,et al.  Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[38]  G. V. Chaitanya,et al.  PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration , 2010, Cell Communication and Signaling.

[39]  J. Downward.  How BAD phosphorylation is good for survival , 1999, Nature Cell Biology.

[40]  H. Shih,et al.  Essential Role of cAMP-response Element-binding Protein Activation by A2A Adenosine Receptors in Rescuing the Nerve Growth Factor-induced Neurite Outgrowth Impaired by Blockage of the MAPK Cascade* , 2002, The Journal of Biological Chemistry.

[41]  D. Alkon,et al.  Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics. , 2010, Pharmacology & therapeutics.

[42]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[43]  D. Green,et al.  Bax-induced Caspase Activation and Apoptosis via Cytochromec Release from Mitochondria Is Inhibitable by Bcl-xL* , 1999, The Journal of Biological Chemistry.

[44]  F. Gage,et al.  Human β nerve growth factor obtained from a baculovirus expression system has potent in vitro and in vivo neurotrophic activity , 1990, Experimental Neurology.

[45]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[46]  J. Bond,et al.  Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target. , 1998, British Journal of Cancer.

[47]  K. Das,et al.  Protein kinase C, an elusive therapeutic target? , 2012, Nature Reviews Drug Discovery.

[48]  X. Liu,et al.  An APAF-1·Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9* , 1999, The Journal of Biological Chemistry.

[49]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[50]  R. Castellani,et al.  Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’ , 2011, The Journal of pathology.

[51]  Reinhard Schliebs,et al.  Basal Forebrain Cholinergic Dysfunction in Alzheimer’s Disease – Interrelationship with β-amyloid, Inflammation and Neurotrophin Signaling , 2005, Neurochemical Research.

[52]  E. Mufson,et al.  The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. , 2005, Journal of neuropathology and experimental neurology.

[53]  Gabriel Gold,et al.  Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.

[54]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[55]  P. Clarke,et al.  Apoptosis and autophagy: Regulation of caspase‐9 by phosphorylation , 2009, The FEBS journal.

[56]  Daniel L. Alkon,et al.  Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials , 2017, Journal of Alzheimer's disease : JAD.

[57]  M. A. Hahn,et al.  Phorbol ester‐induced cell death in PC‐12 cells overexpressing Bcl‐2 is dependent on the time at which cells are treated , 2004, Cell biology international.

[58]  Y. Hwang,et al.  Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by bergamottin via the inhibition of protein kinase Cdelta/p38 mitogen-activated protein kinase and JNK/nuclear factor-kappaB-dependent matrix metalloproteinase-9 expression. , 2010, Molecular nutrition & food research.

[59]  Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations , 2013, Clinical & Experimental Metastasis.

[60]  W. Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[61]  T. Ohyama,et al.  MST, a Physiological Caspase Substrate, Highly Sensitizes Apoptosis Both Upstream and Downstream of Caspase Activation* , 2001, The Journal of Biological Chemistry.

[62]  P. LoRusso,et al.  Clinical experience of MEK inhibitors in cancer therapy. , 2007, Biochimica et biophysica acta.

[63]  M. Holderfield,et al.  Mechanism and consequences of RAF kinase activation by small-molecule inhibitors , 2014, British Journal of Cancer.

[64]  R. Epand,et al.  Protein Kinase C , 1993, British Journal of Cancer.

[65]  F. Gallini.  Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations , 2017 .

[66]  D. Alkon,et al.  Protein Kinase C Activators as Synaptogenic and Memory Therapeutics , 2009, Archiv der Pharmazie.

[67]  K. Becker,et al.  Phorbol Esters: Structure, Biological Activity, and Toxicity in Animals , 2007, International journal of toxicology.

[68]  R. Couch,et al.  Strategizing the Development of Alzheimer’s Therapeutics , 2014 .

[69]  Philip R. Cohen,et al.  MSK1 is required for CREB phosphorylation in response to mitogens in mouse embryonic stem cells , 2000, FEBS letters.

[70]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[71]  P. Fort,et al.  Pro-inflammatory cytokines downregulate Hsp27 and cause apoptosis of human retinal capillary endothelial cells. , 2014, Biochimica et biophysica acta.

[72]  C. McGlade,et al.  Mammalian Numb Proteins Promote Notch1 Receptor Ubiquitination and Degradation of the Notch1 Intracellular Domain* , 2003, Journal of Biological Chemistry.

[73]  M. Prince,et al.  World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .

[74]  W. Kolch,et al.  Protein kinase C alpha activates RAF-1 by direct phosphorylation. , 1993, Nature.

[75]  Bingbing X. Li,et al.  Discovery of a Small‐Molecule Inhibitor of the KIX–KID Interaction , 2009, Chembiochem : a European journal of chemical biology.

[76]  S. Skaper.  Neurotrophic Factors: An Overview. , 2018, Methods in molecular biology.

[77]  P. Ott,et al.  New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy , 2014, Drug, healthcare and patient safety.

[78]  F. Bloom,et al.  Blood-brain barrier penetration and in vivo activity of an NGF conjugate. , 1993, Science.

[79]  Kevin K. W Wang,et al.  Calpain and caspase: can you tell the difference? , 2000, Trends in Neurosciences.

[80]  D. Stern,et al.  Phosphorylation of Plk1 at S137 and T210 is Inhibited in Response to DNA Damage , 2005, Cell cycle.

[81]  F. Lee,et al.  Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027 , 2012, The Journal of Neuroscience.

[82]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[83]  Zhe Zhang,et al.  Protein kinase C-α (PKCα) modulates cell apoptosis by stimulating nuclear translocation of NF-kappa-B p65 in urothelial cell carcinoma of the bladder , 2017, BMC Cancer.

[84]  Walter Kolch,et al.  Protein kinase Cα activates RAF-1 by direct phosphorylation , 1993, Nature.

[85]  Ming-Sound Tsao,et al.  An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.

[86]  E. Petricoin,et al.  Reverse phase protein microarrays for monitoring biological responses. , 2007, Methods in molecular biology.

[87]  F. Gage,et al.  Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. , 1988, Science.